Pacbio Expands Distribution in China, Gaining Access to New Clinical Lab Networks Via Haorui Gene

Published: 2025-05-22 13:06:01 ET PACB

Published on 05/22/2025 at 13:06

PacBio announced the appointment of Haorui Gene as an official distributor in China. The distribution arrangement is designed to expand access to PacBio's HiFi long-read sequencing technology in clinical and research settings, with a focus on transfusion medicine and hematology, areas where precision and completeness of genomic data are critical to patient outcomes. Founded in 2020, Haorui Gene has quickly become a key player in blood typing genomics, deploying seven Sequel II and three Revio systems across China to support large-scale efforts in HLA typing, blood group genotyping, and rare blood type discovery.

Through these programs, Haorui has helped set new standards for resolution and reliability in complex genomic regions, delivering insights that are often missed by traditional methods. This marks an important step toward establishing PacBio's HiFi sequencing as the method of choice in blood genomics, offering exceptional accuracy across full-length genes, structural variants, and highly polymorphic regions that are critical for transfusion safety and donor matching. With over 20 peer-reviewed publications and widespread adoption in Chinese blood centers, Haorui's work demonstrates the clinical and scientific momentum behind long-read sequencing as a foundational tool for the future of personalized transfusion medicine.

Under the terms of the agreement, Haorui Gene will distribute PacBio's Vega platform throughout China, which, together with other products offered by Haorui Gene, will deliver end-to-end support for clinical laboratories, blood centers, and genomics institutions aiming to build more complete, confident blood group profiles. Haorui Gene has played a leading role in bringing advanced long-read sequencing into clinical use across China. In 2022, the company introduced a HiFi-based HLA typing product, followed by comprehensive blood group genotyping panels in 2023.

In 2024, Haorui expanded its collaborations with major blood centers to deepen national research efforts in rare blood classification and erythrocyte antigen mapping, areas that demand high-resolution, allele-level insight. This expanded partnership supports one of the world's fastest-growing clinical genomics markets and reflects a shared commitment to making high-precision sequencing more widely available for healthcare applications that depend on accuracy at scale.